Fujimoto, J.M., et al., “Narcotic Antagonist Activity of Several Metabolites of Naloxone and Naltrexone Tested in Morphine Dependent Mice,” Proceedings of the Society for Experimental Biology and Medicine, 148:443-448 (1975). |
Wang, Z., et al., “Constitutive μ Opioid Receptor Activation as a Regulatory Mechanism Underlying Narcotic Tolerance and Dependence,” Life Sciences, 54(20):PL339-350 (1994). |
Bilsky, E.J., et al., “Effects of Naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the Protein Kinase Inhibitors H7 and H8 on Acute Morphine Dependence and Antinociceptive Tolerance in Mice,” The Journal of Pharmacology and Experimental Therapeutics, 277(1):484-490 (1996). |
Ferrari, A., et al., “Serum Time Course of Naltrexone and 6β-Naltrexol Levels During Long Term Treatment in Drug Addicts,” Drug and Alcohol Dependence, 52:211-220 (1998). |
Gardner, E.L., “Brain Reward Mechanisms”. In Substance Abuse. A Comprehensive Textbook, Fisher, M.G., eds., (MD:Williams & Wilkins), pp. 70-99 (1992). |
Nestler, E. J., “Molecular Mechanisms of Drug Addiction,” The Journal of Neuroscience, 12(7):2439-2450 (1992). |
Chatterjie, N., and Inturrisi, C.E., “Stereospecific Synthesis of the 6β-Hydroxy Metabolites of Naltrexone and Naloxone,” Journal of Medicinal Chemistry, 18(5):490-492 (1975). |
Jiang, J.B., et al., “Stereochemical Studies on Medicinal Agents. 23.1 Synthesis and Biological Evaluation of 6-Amino Derivatives of Naloxone and Naltrexone,” Journal of Medicinal Chemistry, 20(8):1100-1102 (1977). |
Burford, N.T., et al., “Specific G Protein Activation and μ-opioid Recepter Internalization Caused by Morphine, DAMGO and Endomorphin I,” European Journal of Pharmacology, 342:123-126 (1998). |
Wang, Danxin, et al., “Calmodulin Binding to G Protein-coupling Domain of Opioid Receptors,” The Journal of Biological Chemistry, 274(31):22081-22088 (1999). |
Burford, N.T., et al., “G-Protein Coupling of μ-Opioid Receptors (OP3) : Elevated Basal Signalling Activity,” Biochemical Journal, 348:531-537 (2000). |
Wang, Danxin, et al., “Calmodulin Regulation of Basal and Agonist-Stimulated G Protein Coupling by the μ-Opioid Receptor (OP3) in Morphine-Pretreated Cells,” Journal of Neurochemistry, 75(2):763-771 (2000). |
Comer, S.D., et al., “Clocinnamox: A Novel, Systemically-Active, Irreversible Opioid Antagonist1,2,3”, The Journal of Pharmacology and Experimental Therapeutics, 262(3):1051-1056 (1992). |
Palmer, R. B., et al., “(E) -and (Z)-7-Arylidenenaltrexones: Synthesis and Opioid Receptor Radioligand Displacement Assays,” J. Med. Chem., 40(5):749-753 (1997). |
Neilan, C.L., et al., “Constitutive Activity of the δ-Opioid Receptor Expressed in C6 Glioma Cells: Identification of Non-Peptide δ-Inverse Agonists,” British Journal of Pharmacology, 128(3):556-562 (1999). |
Wong, Y.H., “Gi Assays in Transfected Cells,” Methods in Enzymology, 238:81-94 (1994). |
Porreca, F., et al., “Roles of Mu, Delta and Kappa Opioid Receptors in Spinal and Supraspinal Mediation of Gastrointestinal Transit Effects and Hot-Plate Analgesia in the Mouse”, The Journal of Pharmacology and Experimental Therapeutics, 230(2):341-348 (1984). |
Plapp, B.V., “Control of Alcohol Metabolism”. In Toward a Molecular Basis of Alcohol Use and Abuse, B. Jansson, et al., ed., (Birkhäuser Verlag Basel/Switzerland), pp. 311-322 (1994). |
Yano, I., and Takemori, A.E., “Inhibition by Naloxone of Tolerance and Dependence in Mice Treated Acutely and Chronically with Morphine,” Research Communications in Chemical Pathology and Pharmacology, 16(4):721-734 (1977). |
Abstract for Accession No. 1993-406332/199351 from World Patent Index Database compiled by Derwent Information Limited. |